Autolus Therapeutics PLC (AUTL)

Autolus Therapeutics experienced two recent insider transactions totaling approximately $31,360 in sales. U.S. CCO Cintia Piccina executed these disposals following the company's latest earnings report, which showed a 28.57% EPS beat. The stock has risen 28.9% over the past ninety days, currently trading near the midpoint of its annual price range.
Ticker: AUTL Exchange: NSM


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
Piccina Cintia U.S. CCO & Country Gen Manager Officer
Transaction date
Sale
Price
72.56
Quantity 30,229 -11.1%
Value US$3,149,357
2.9
Piccina Cintia Officer Officer
Transaction date
Proposed sale
Price
257.32
Quantity 87,378
Value US$793,531
2.9
Martin Pule Officer Officer
Transaction date
Proposed sale
Price
21.69
Quantity 97,704
Value US$3,374,146
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-09-03 2026-09-02 S Sale

U.S. CCO & Country Gen Manager

Officer
30,229 -11.1%
72.56
US$3,149,357
30,229 -11.1% 72.56 US$3,149,357
2026-09-02 2026-09-02 PrS Proposed sale

Officer

Officer
87,378
257.32
US$793,531
87,378 257.32 US$793,531
2024-09-16 2024-09-16 PrS Proposed sale

Officer

Officer
97,704
21.69
US$3,374,146
97,704 21.69 US$3,374,146